Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis
We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin’s lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003–12/2007 were included into this analysis. At cerebral...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | deu |
| Published: |
German Medical Science GMS Publishing House
2011-01-01
|
| Series: | GMS German Medical Science |
| Subjects: | |
| Online Access: | http://www.egms.de/en/journals/gms/2011-9/000134.shtml |
| _version_ | 1818351245614645248 |
|---|---|
| author | Patrij, Katrin Kowoll, Annika Wätzel, Luise Reiser, Marcel Pels, Hendrik Linnebank, Michael Engert, Andreas Herrlinger, Ulrich Schackert, Gabriele Vogt-Schaden, Marlies Egerer, Gerlinde Lamprecht, Monika Batchelor, Tracy T. Schlegel, Uwe Schmidt-Wolf, Ingo G. H. International Primary CNS Lymphoma Collaborative Group (IPCG) |
| author_facet | Patrij, Katrin Kowoll, Annika Wätzel, Luise Reiser, Marcel Pels, Hendrik Linnebank, Michael Engert, Andreas Herrlinger, Ulrich Schackert, Gabriele Vogt-Schaden, Marlies Egerer, Gerlinde Lamprecht, Monika Batchelor, Tracy T. Schlegel, Uwe Schmidt-Wolf, Ingo G. H. International Primary CNS Lymphoma Collaborative Group (IPCG) |
| author_sort | Patrij, Katrin |
| collection | DOAJ |
| description | We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin’s lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003–12/2007 were included into this analysis. At cerebral relapse, 15/23 patients were treated with a regimen consisting of high-dose methotrexate (Bonn protocol). After a median follow-up of 6.5 months (range 1–68), 15/23 (65%) patients with SCNSL had relapsed or progressed. HD (high-dose)- methotrexate (MTX) chemotherapy according to the Bonn protocol is effective concerning response rates; however, overall survival of patients with SCNSL seems to be impaired in comparison to relapses in primary CNSL (PCNSL). |
| first_indexed | 2024-12-13T18:34:41Z |
| format | Article |
| id | doaj.art-2e92555b387b487bb51794fc2ce8bad0 |
| institution | Directory Open Access Journal |
| issn | 1612-3174 |
| language | deu |
| last_indexed | 2024-12-13T18:34:41Z |
| publishDate | 2011-01-01 |
| publisher | German Medical Science GMS Publishing House |
| record_format | Article |
| series | GMS German Medical Science |
| spelling | doaj.art-2e92555b387b487bb51794fc2ce8bad02022-12-21T23:35:23ZdeuGerman Medical Science GMS Publishing HouseGMS German Medical Science1612-31742011-01-019Doc11Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysisPatrij, KatrinKowoll, AnnikaWätzel, LuiseReiser, MarcelPels, HendrikLinnebank, MichaelEngert, AndreasHerrlinger, UlrichSchackert, GabrieleVogt-Schaden, MarliesEgerer, GerlindeLamprecht, MonikaBatchelor, Tracy T.Schlegel, UweSchmidt-Wolf, Ingo G. H.International Primary CNS Lymphoma Collaborative Group (IPCG)We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin’s lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003–12/2007 were included into this analysis. At cerebral relapse, 15/23 patients were treated with a regimen consisting of high-dose methotrexate (Bonn protocol). After a median follow-up of 6.5 months (range 1–68), 15/23 (65%) patients with SCNSL had relapsed or progressed. HD (high-dose)- methotrexate (MTX) chemotherapy according to the Bonn protocol is effective concerning response rates; however, overall survival of patients with SCNSL seems to be impaired in comparison to relapses in primary CNSL (PCNSL).http://www.egms.de/en/journals/gms/2011-9/000134.shtmllymphomaneoplasiachemotherapyCNSrelapsemethotrexate |
| spellingShingle | Patrij, Katrin Kowoll, Annika Wätzel, Luise Reiser, Marcel Pels, Hendrik Linnebank, Michael Engert, Andreas Herrlinger, Ulrich Schackert, Gabriele Vogt-Schaden, Marlies Egerer, Gerlinde Lamprecht, Monika Batchelor, Tracy T. Schlegel, Uwe Schmidt-Wolf, Ingo G. H. International Primary CNS Lymphoma Collaborative Group (IPCG) Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis GMS German Medical Science lymphoma neoplasia chemotherapy CNS relapse methotrexate |
| title | Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis |
| title_full | Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis |
| title_fullStr | Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis |
| title_full_unstemmed | Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis |
| title_short | Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis |
| title_sort | isolated central nervous system relapse of systemic lymphoma scnsl clinical features and outcome of a retrospective analysis |
| topic | lymphoma neoplasia chemotherapy CNS relapse methotrexate |
| url | http://www.egms.de/en/journals/gms/2011-9/000134.shtml |
| work_keys_str_mv | AT patrijkatrin isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT kowollannika isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT watzelluise isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT reisermarcel isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT pelshendrik isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT linnebankmichael isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT engertandreas isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT herrlingerulrich isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT schackertgabriele isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT vogtschadenmarlies isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT egerergerlinde isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT lamprechtmonika isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT batchelortracyt isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT schlegeluwe isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT schmidtwolfingogh isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis AT internationalprimarycnslymphomacollaborativegroupipcg isolatedcentralnervoussystemrelapseofsystemiclymphomascnslclinicalfeaturesandoutcomeofaretrospectiveanalysis |